Table 1 Baseline characteristics of all patients divided in the retinopathy cohort and kidney disease cohort, respectively

Number

10,289

11,857

Age, yrs

21 (19–26)

21 (19–26)

Males

58.1%

57.3%

Debut age, yrs

16 (11–21)

15 (10–21)

 0–10 yrs

18.3%

22.9%

 10–15 yrs

26.3%

25.7%

 15–20 yrs

23.7%

21.9%

 20–25 yrs

18.9%

17.6%

 25–30 yrs

12.7%

11.9%

Duration, yrs

6 (3–9)

7 (3–10)

Follow-up time, yrs

4.8 (2.6–7.7)

5.4 (2.9–8.7)

eGDR measurements per individual

4 (2–6)

4 (2–7)

eGDR, mg/kg/min

9.0 (8.0–9.8)

8.9 (8.0–9.7)

 < 4

1.7%

1.5%

 4 ≤ to < 6

5.1%

5.0%

 6 ≤ to < 8

18.5%

19.4%

 ≥ 8

74.8%

74.1%

LDL-cholesterol, mmol/L

2.43 (1.97–2.96)

2.43 (1.98–2.98)

 < 2.6

59.1%

58.6%

 2.6 ≤ to < 3.4

28.3%

28.3%

 3.4 ≤ to < 4.1

8.9%

9.3%

 ≥ 4.1

3.6%

3.8%

HDL-cholesterol, mmol/L

1.4 (1.2–1.7)

1.4 (1.2–1.7)

 < 1.1

13.1%

13.2%

 ≥ 1.1

86.9%

86.8%

Total-cholesterol, mmol/L

4.4 (3.8–5.0)

4.4 (3.8–5.0)

 < 4.5

54.5%

53.9%

 ≥ 4.5

45.5%

46.1%

Triglyceride, mmol/L

0.90 (0.62–1.28)

0.90 (0.66–1.30)

  < 1.7

86.5%

86.1%

  ≥ 1.7

13.5%

13.9%

HbA1c, mmol/mol

60 (51–71)

61 (52–72)

 < 48

17.2%

16.4%

 48 ≤ to < 58

24.9%

23.8%

 58 ≤ to < 70

29.7%

30.5%

 ≥ 70

28.2%

29.2%

BMI (Kg/m²)^*

23.6 (21.6–26.2)

23.4 (21.3–26.1)

 Normal

64.5%

65.4%

 Overweight

26.3%

25.7%

 Obese

9.2%

8.9%

Smokers

11.0%

11.3%

Physical activity; daily

18.2%

17.6%

Physical activity; 3–5 times/week

33.2%

33.6%

Physical activity; 1–2 times/week

26.2%

26.9%

Physical activity; < 1 times/week

14.1%

13.7%

Physical activity; never

8.3%

8.1%

Insulin method; injection

81.3%

79.5%

Insulin method; pump

18.7%

20.5%

ASA; yes

0.8%

0.7%

Antihypertensive therapy; yes

3.5%

3.0%

Lipid lowering drug; yes

3.0%

2.6%

Hypertension

5.2%

5.0%

eGFR, mL/min

123 (106–145)

124 (107–147)

 < 30

0.06%

0.03%

 30 ≤ to < 45

0.03%

0.02%

 45 ≤ to < 60

0.13%

0.10%

 60 ≤ to < 90

7.26%

6.79%

 ≥ 90

92.53%

93.06%